Bayer AG’s OTC pain relief category had sales growth of 9% in the third quarter and its allergy and cold segment's sales increased 6.4% as its consumer health business shows some recovery while it continues implementing turnaround strategies.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?